Kamel Mahmoud M, Saad Mohamed F, Mahmoud Amal A, Edries Awatief A, Abdel-Moneim Ahmed S
College of Medicine, Taif University, Al-Taif 21944, Saudi Arabia; Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
College of Medicine, Taif University, Al-Taif 21944, Saudi Arabia.
Microb Pathog. 2014 Dec;77:31-5. doi: 10.1016/j.micpath.2014.10.009. Epub 2014 Oct 22.
Viral hepatitis is the most significant predisposing factor for hepatocellular carcinoma (HCC). Liver cancer grows silently with mild or no symptoms until the disease is advanced and with little hope of cure. Early recognition of the onset of HCC would help to select more effective therapies for patients leading to a better prognosis and life span. The current study aims to evaluate two diagnostic and prognostic markers - Prothrombin induced by vitamin K absence-II (PIVKA-II) and macrophage migration inhibitory factor (MIF) in the serum of patients with HCC and those with a high risk of developing hepatic cancers. Serum samples from hepatocellular carcinoma, hepatitis C and normal subjects were subjected to quantitative determinations of different parameters including alpha-fetoprotein (AFP), PIVKA-II and MIF. Significant differences between the various groups were recorded. PIVKA-II and AFP showed a higher specificity and sensitivity compared to MIF, and there was considerable correlation between AFP and both PIVKA and MIF. It is concluded that analysis of PIVKA-II and AFP can serve as useful non-invasive markers for the early detection of HCC with good sensitivity and specificity.
病毒性肝炎是肝细胞癌（HCC）最重要的诱发因素。肝癌在病情进展之前通常悄无声息地发展，症状轻微或没有症状，治愈的希望渺茫。早期识别HCC的发病有助于为患者选择更有效的治疗方法，从而获得更好的预后和更长的寿命。本研究旨在评估两种诊断和预后标志物——维生素K缺乏诱导蛋白-II（PIVKA-II）和巨噬细胞移动抑制因子（MIF）在HCC患者及肝癌高危患者血清中的情况。对肝细胞癌、丙型肝炎患者和正常受试者的血清样本进行了包括甲胎蛋白（AFP）、PIVKA-II和MIF在内的不同参数的定量测定。记录了各组之间的显著差异。与MIF相比，PIVKA-II和AFP表现出更高的特异性和敏感性，并且AFP与PIVKA和MIF之间存在显著相关性。研究得出结论，PIVKA-II和AFP分析可作为早期检测HCC的有用非侵入性标志物，具有良好的敏感性和特异性。
